Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Implement best practices for the accurate diagnosis and risk stratification of non–muscle-invasive bladder cancer (NMIBC)
• Describe the mechanisms of action and supporting clinical trial data for recently approved and emerging therapies in NMIBC
• Integrate novel therapies into personalized care plans for patients with NMIBC
• Apply multidisciplinary care strategies to optimize outcomes in patients with NMIBC, including management of treatment-related AEs and effective coordination of care

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Ferring Pharmaceuticals.

Chair:

Ashish M. Kamat, MD, MBBS

Professor of Urologic Oncology
Wayne B. Duddlesten Professor of Cancer Research
Director, Bladder Cancer Research
President, International Bladder Cancer Group
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas Pharma, Atonco Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, UroGen Pharma, US Biotest, Valar Labs, Vivet Therapeutics; Grant/Research Funding: Arquer Diagnostics, EnGene, FKD Therapies (now Ferring), Patient-Centered Outcomes Research Institute, Photocure, Seagen, SWOG; Joint Patent with MD Anderson Cancer Center: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); Leadership/Fiduciary Role: American Urological Association, European Urology Oncology, International Bladder Cancer Group, Journal of Urology, UroToday, World Bladder Cancer Patient Coalition

Faculty:

Katie S. Murray, DO, MS

Professor, Department of Urology at NYU Grossman
School of Medicine
Chief, Urology Service, Bellevue Hospital Center
NYU Langone
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Curium, Ferring Pharmaceuticals, Relmada, UroGen Pharma

Thomas Powles, MD, MBBS, MRCP

Professor of Genitourinary Oncology
Director and Lead for Solid Tumor Research
Barts Cancer Centre at St Bartholomew’s Hospital
London, UK

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, MSD, Novartis, Pfizer; Grant/Research Funding: AstraZeneca, Bristol Myers Squibb, Exelixis, Ipsen, MSD, Novartis, Pfizer, Roche, Seattle Genetics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member.

Release Date

March 6, 2026

Expiration Date

March 6, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.